Angiodynamic Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 8.19
Dividend & YieldN/A$ (N/A)
Beta 0.73
Market capitalization 489.24M
Operating cash flow -23.04M
ESG Scores unknown

Company description

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Sector: Healthcare - Industry: Medical Instruments & Supplies

Financial Ratios
Quick Ratio1.6
Working Capital-0.38
Return On Equity-0.07
Debt To Equity0.05
Fixed Asset Ratio0.34
Fixed Interest Cover-17.38

Financial data

Financial Statements

Cashflow Statement 2019-05-31 2020-05-31 2021-05-31 2022-05-31
Change To Liabilities 5.21M -15.47M 4.88M 3.91M
Total Cashflows From Investing Activities 82.55M -63.34M -13.71M -19.31M
Net Borrowings 40M -92.5M -20M 5M
Total Cash From Financing Activities 33.93M -95.24M -16.99M 7.68M
Change To Operating Activities -1.87M -6.16M -3.18M -5.01M
Issuance Of Stock 2.03M 3.01M 3.01M 2.68M
Net Income 61.34M -166.79M -31.55M -26.55M
Change In Cash 153.54M -173.21M -6.27M -19.34M
Effect Of Exchange Rate -380k -65k 330k -518k
Total Cash From Operating Activities 37.44M -14.55M 24.09M -7.19M
Depreciation 25.88M 23.8M 25.92M 29.35M
Change To Account Receivables -3.18M 11.92M -4.16M -17.15M
Other Cashflows From Financing Activities -8.1M -2.74M
Change To Netincome -48.52M 156.98M 20.65M 11.05M
Capital Expenditures -3.12M -7.24M -5.19M -4.3M

Income Statement 2019-05-31 2020-05-31 2021-05-31 2022-05-31
Research Development 28.26M 29.68M 35.83M 30.98M
Income Before Tax -14.7M -168.13M -36.05M -29.95M
Net Income 61.34M -166.79M -31.55M -26.55M
Selling General Administrative 111.73M 116.51M 118.98M 136.81M
Gross Profit 156M 150.27M 156.09M 164.93M
Ebit -1.04M -14.04M -16.86M -22.32M
Operating Income -1.04M -14.04M -16.86M -22.32M
Interest Expense -5.1M -907k -861k -688k
Income Tax Expense -3.56M -1.35M -4.5M -3.4M
Total Revenue 270.63M 264.16M 291.01M 316.22M
Cost Of Revenue 114.63M 113.89M 134.92M 151.29M
Total Other Income ExpenseNet -13.66M -154.1M -19.19M -7.63M
Net Income From Continuing Ops -11.15M -166.79M -31.55M -26.55M
Net Income Applicable To Common Shares 61.34M -166.79M -31.55M -26.55M

Balance Sheet Statement 2019-05-31 2020-05-31 2021-05-31 2022-05-31
Total Liabilities 221.62M 139.34M 121.98M 128.26M
Total Stockholder Equity 614.82M 454.87M 439.46M 424.49M
Other Current Liabilities 12.14M 5.89M 1.05M 8.88M
Total Assets 836.44M 594.21M 561.44M 552.75M
Common Stock 372k 374k 377k 380k
Other Current Assets 3.55M 2.85M 5.97M 5.89M
Retained Earnings 66.47M -100.32M -131.87M -158.41M
Treasury Stock -7.07M -7.05M -2.56M -4.36M
Cash 227.64M 54.44M 48.16M 28.82M
Total Current Liabilities 73.3M 51.45M 57.58M 74.32M
Other Stockholder Equity -1.35M -1.34M 3.15M 1.36M
Property, Plant, and Equipment 24.26M 38.46M 46.45M 51.98M
Total Current Assets 315.29M 152.91M 140.88M 143.34M
Net Tangible Assets 121.76M 57.22M 69.16M 71.05M
Net Receivables 43.58M 34.17M 37.32M 56.5M
Accounts Payable 22.83M 19.1M 19.63M 28.05M


Insider Transactions

Here are the insider transactions of stock shares related to Angiodynamic Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
TROWBRIDGE STEPHEN APurchase at price 13.82 per share.D2022-10-12Chief Financial Officer1.08k
CLEMMER JAMES CPurchase at price 15.00 per share.D2022-10-10Chief Executive Officer10k
HELSEL DAVID DSale at price 22.44 per share.D2022-07-29Officer5k
METENY DENNIS SStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
JOHNSON WESLEY E JRStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
AUEN EILEEN O SHEAStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
ROSENZWEIG RICHARD CStock Award(Grant) at price 0.00 per share.D2022-07-20General Counsel3.96k
REED JAN STERNStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
DONNELLY HOWARD WStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
CLEMMER JAMES CStock Award(Grant) at price 0.00 per share.D2022-07-20Chief Executive Officer33.09k
NIGHAN WARREN G JRStock Award(Grant) at price 0.00 per share.D2022-07-20Officer3.43k
HELSEL DAVID DStock Award(Grant) at price 0.00 per share.D2022-07-20Officer3.69k
TARNOFF MICHAEL EStock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
TROWBRIDGE STEPHEN AStock Award(Grant) at price 0.00 per share.D2022-07-20Chief Financial Officer7.96k
CAMPBELL CHAD THOMASStock Award(Grant) at price 0.00 per share.D2022-07-20Officer3.99k
LICITRA KAREN A.Stock Award(Grant) at price 0.00 per share.D2022-07-20Director7.06k
CENTEA SCOTTStock Award(Grant) at price 0.00 per share.D2022-07-20Officer3.71k
PICCININI LAURAStock Award(Grant) at price 0.00 per share.D2022-07-20Officer4.4k
JOHNSON WESLEY E JRConversion of Exercise of derivative security at price 15.95 per share.D2022-07-15Director6.02k
TROWBRIDGE STEPHEN AConversion of Exercise of derivative security at price 15.95 per share.D2022-07-15Chief Financial Officer14.76k
METENY DENNIS SConversion of Exercise of derivative security at price 15.95 per share.D2022-07-12Director6.02k
CLEMMER JAMES CD2022-07-07Chief Executive Officer25.12k
NIGHAN WARREN G JRD2022-07-07Officer3.23k
HELSEL DAVID DD2022-07-07Officer3.48k
TROWBRIDGE STEPHEN AD2022-07-07Chief Financial Officer4.19k
CAMPBELL CHAD THOMASD2022-07-07Officer3.1k
HELSEL DAVID DSale at price 22.44 per share.D2022-04-28Officer3.51k
DONNELLY HOWARD WConversion of Exercise of derivative security at price 15.95 per share.D2022-04-20Director6.02k
JOHNSON WESLEY E JRSale at price 23.00 - 23.26 per share.D2022-04-12Director7.5k
TROWBRIDGE STEPHEN APurchase at price 22.64 per share.D2022-01-12Chief Financial Officer1k
CLEMMER JAMES CPurchase at price 22.84 per share.D2022-01-11Chief Executive Officer10k
HELSEL DAVID DSale at price 27.97 per share.D2021-10-20Officer3.49k
CENTEA SCOTTSale at price 27.92 per share.D2021-10-15Officer12k
CENTEA SCOTTConversion of Exercise of derivative security at price 16.77 per share.D2021-10-15Officer12k
CAMPBELL CHAD THOMASSale at price 27.15 per share.D2021-10-05Officer10.75k
CAMPBELL CHAD THOMASConversion of Exercise of derivative security at price 16.59 per share.D2021-10-05Officer10.75k
CLEMMER JAMES CD2021-08-12Chief Executive Officer19.39k
CLEMMER JAMES CD2021-08-12Chief Executive Officer40.53k
HELSEL DAVID DD2021-08-12Officer2.69k
HELSEL DAVID DD2021-08-12Officer11.41k
TROWBRIDGE STEPHEN AD2021-08-12Chief Financial Officer3.23k
TROWBRIDGE STEPHEN AD2021-08-12Chief Financial Officer10.95k
CAMPBELL CHAD THOMASD2021-08-12Officer2.4k
CAMPBELL CHAD THOMASD2021-08-12Officer8.21k
METENY DENNIS SConversion of Exercise of derivative security at price 14.64 per share.D2021-07-28Director5.73k
JOHNSON WESLEY E JRConversion of Exercise of derivative security at price 14.64 per share.D2021-07-28Director5.73k
METENY DENNIS SStock Award(Grant) at price 0.00 per share.D2021-07-21Director5.74k
JOHNSON WESLEY E JRStock Award(Grant) at price 0.00 per share.D2021-07-21Director5.74k
AUEN EILEEN O SHEAStock Award(Grant) at price 0.00 per share.D2021-07-21Director5.74k
ROSENZWEIG RICHARD CStock Award(Grant) at price 0.00 per share.D2021-07-21General Counsel3.1k
ROSENZWEIG RICHARD CStock Award(Grant) at price 0.00 per share.D2021-07-21General Counsel3.1k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Angiodynamic Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Angiodynamic Inc

Here is the result of two systematic investment strategies applied to Angiodynamic Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Angiodynamic Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Angiodynamic Inc:

Angiodynamic Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 97.89% on the backtest period.

Performance at glance

Performance

97.89 %

Latent gain

1731.14 $

Invested capital

1768.47 $

Annualized return

23.88 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Angiodynamic Inc

This is the result of two momentum investment strategies applied to Angiodynamic Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Angiodynamic Inc

The following chart shows all the entries opened by the momentum investment system on Angiodynamic Inc:

Angiodynamic Inc momentum entries
  • The first momentum investment strategy would give 90.95% of return on Angiodynamic Inc. That represents 4100.88$ of latent gain with 4508.78$ of employed capital.
  • The second momentum investment strategy would give 115.28% of return on Angiodynamic Inc. That represents 4643.55$ of latent gain with 4028.05$ of employed capital.
Performance at glance (1Q Momentum)

Performance

90.95 %

Latent gain

4100.88 $

Invested capital

4508.78 $

Annualized return

59.67 %
Performance at glance (2Q Momentum)

Performance

115.28 %

Latent gain

4643.55 $

Invested capital

4028.05 $

Annualized return

31.85 %

Momentum equity curve on Angiodynamic Inc

The following chart shows the equity curve of the two momentum strategies applied to Angiodynamic Inc:

Angiodynamic Inc momentum equity

Note: the dividends potentially given by Angiodynamic Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Angiodynamic Inc

The following chart shows the employed capital evolution of the two momentum strategies on Angiodynamic Inc since the beginning:

Angiodynamic Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Angiodynamic Inc

Buy the dip entry openings on Angiodynamic Inc

Angiodynamic Inc

The performance achieved by the robo-advisor on Angiodynamic Inc is 125.3%. That represents 2187.43$ of latent gain with 1745.76$ of employed capital. The following chart shows Angiodynamic Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Angiodynamic Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

125.3 %

Latent gain

2187.43 $

Invested capital

1745.76 $

Annualized return

59.67 %

Equity curve of the strategy applied to Angiodynamic Inc

The following chart shows the result of the investment strategy applied to Angiodynamic Inc:

Angiodynamic Inc

Note: the dividends potentially given by Angiodynamic Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Angiodynamic Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Angiodynamic Inc:

Angiodynamic Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Angiodynamic Inc

In this section, I will compare the three previous investment strategies applied to Angiodynamic Inc.

Equity curve comparison on Angiodynamic Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Angiodynamic Inc investment strategy comparison

Employed capital comparison on Angiodynamic Inc

Angiodynamic Inc investment comparison

Performance comparison on Angiodynamic Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 97.89% 1731.14$ 1768.47$ 23.88%
Momentum 1 quarter 90.95% 4100.88$ 4508.78$ 23.56%
Momentum 2 quarters 115.28% 4643.55$ 4028.05$ 31.85%
Non-directional 125.3% 2187.43$ 1745.76$ 59.67%
Annualized return comparison

Automatic investment

23.88 %

Momentum 1Q

31.85 %

Momentum 2Q

31.85 %

Non-directional

59.67 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Angiodynamic Inc:

Positive correlations

Most correlated stocks this year

  • Angiodynamic Inc

  • Most correlated stocks last 3 months

  • Angiodynamic Inc
  • EMPEROR E HOTEL
  • COURTOIS

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Invesco BulletShares 2021 Corporate Bond ETF

  • Note: The algorithm computes the probability of correlation between Angiodynamic Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Angiodynamic Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Angiodynamic Inc
    Country United States
    City Latham
    Address 14 Plaza Drive
    Phone 518 795 1400
    Website www.angiodynamics.com
    FullTime employees 760
    Industry Medical Instruments & Supplies
    Sector Healthcare
    Exchange XNAS
    Ticker ANGO
    Market www.nasdaq.com

    Angiodynamic Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown